Berylliosis

Last updated
Berylliosis
Other namesChronic beryllium disease (CBD)
Chronic berylliosis (8054314225).jpg
Peribronchal non-necrotizing granuloma from berylliosis
Specialty Pulmonology

Berylliosis, or chronic beryllium disease (CBD), is a chronic allergic-type lung response and chronic lung disease caused by exposure to beryllium and its compounds, a form of beryllium poisoning. It is distinct from acute beryllium poisoning, which became rare following occupational exposure limits established around 1950. [1] Berylliosis is an occupational lung disease.

Contents

While there is no cure, symptoms can be treated. [2]

Signs and symptoms

With single or prolonged exposure by inhalation the lungs may become sensitized to beryllium. Berylliosis has a slow onset and progression. Some people who are sensitized to beryllium may not have symptoms. [1] Continued exposure causes the development of small inflammatory nodules, called granulomas. [3] Of note, the authors of a 2006 study suggested that beryllium inhalation was not the only form of exposure and perhaps skin exposure was also a cause, as they found that a reduction in beryllium inhalation did not result in a reduction in chronic beryllium disease or beryllium sensitization. [4]

Granuloma formation is seen in other diseases such as tuberculosis and sarcoidosis. Sarcoidosis, like berylliosis, also produces granulomas without a necrotic core, and so distinction between the two processes can be difficult.

Ultimately, this process leads to restrictive lung disease (a decrease in diffusion capacity).

The earliest symptoms are typically cough and shortness of breath. [5] Other symptoms include chest pain, joint aches, weight loss, and fever.

Rarely, one can get granulomas in other organs including the liver.

The onset of symptoms can range from weeks up to tens of years from the initial exposure. In some individuals, a single exposure to beryllium can cause berylliosis.

Pathogenesis

In susceptible persons, beryllium exposure can lead to a cell-mediated immune response. The T-cells become sensitized to beryllium. Each subsequent exposure leads to an immune response involving CD4+ helper T-lymphocytes and macrophages accumulating in the lungs. As this response continues macrophages, CD+4 T-lymphocytes and plasma cells aggregate together to form the noncaseating granulomas. [6] [7] When beryllium is phagocytized by macrophages, the beryllium triggers macrophage apoptosis, thereby reducing beryllium clearance from the lungs and eventually resulting in secondary necrosis and lysis. [8] Eventually, the outcome is fibrosis of the lung. [9] [10]

Several studies have shown that there is a genetic component to beryllium sensitivity. Specifically, those beryllium-exposed workers with a mutation at the HLA-DPB1 Glu69 position have increased prevalence of beryllium sensitization and chronic beryllium disease. [11] The HLA-DPB1 gene is important for MHC class II molecule function on antigen presenting cells. [11] A study of the immune response to beryllium in individuals who express the HLA-DP2 allele found that CD4 T-cells do not detect the Be+ cation itself, but instead detect surface changes in the HLA-DP2/peptide complex in which Be+ is embedded. Those researchers concluded that chronic beryllium disease is a predisposition that lies between "allergic hypersensitivity and autoimmunity." [12]

According to the International Agency for Research on Cancer, beryllium and beryllium compounds are Category 1 carcinogens; they are carcinogenic to both animals and humans. [13]

Diagnosis

X-ray image of a 54-year-old man working in the aerospace manufacturing industry with berylliosis Chronic beryllioisis - Case 293 (15528999565).jpg
X-ray image of a 54-year-old man working in the aerospace manufacturing industry with berylliosis

The differential diagnosis for berylliosis includes: [14]

Diagnosis of berylliosis is based on history of beryllium exposures, documented beryllium sensitivity, and granulomatous inflammation on lung biopsy. Given the invasive nature of a lung biopsy, diagnosis can also be based on clinical history consistent with berylliosis, abnormal chest x-ray or CT scan findings, and abnormalities in pulmonary function tests. [15]

The radiologic and pathologic features of berylliosis are very similar to sarcoidosis. Due to the strong clinical and histopathological resemblance of sarcoidosis and berylliosis, patients are sometimes misdiagnosed with sarcoidosis until the history of exposure to beryllium is elicited and beryllium hypersensitivity demonstrated with specific testing. Some studies suggest that up to 6% of all cases of sarcoidosis are actually berylliosis. [16] [17]

The beryllium lymphocyte proliferation test (BeLPT) is the standard way of determining sensitivity to beryllium. [15] The test is performed by acquiring either peripheral blood or fluid from a bronchial alveolar lavage, and lymphocytes are cultured with beryllium sulfate. Cells are then counted and those with elevated number of cells are considered abnormal. [18] Those exposed persons with two abnormal BeLPT tested with peripheral blood, or one abnormal and one borderline result, are considered beryllium sensitized. Also, those with one abnormal BeLPT tested with fluid from a bronchial alveolar lavage are considered sensitized. [15]

Chest radiography findings of berylliosis are non-specific. Early in the disease radiography findings are usually normal. In later stages interstitial fibrosis, pleural irregularities, hilar lymphadenopathy and ground-glass opacities have been reported. [19] [20] Findings on CT are also not specific to berylliosis. Findings that are common in CT scans of people with berylliosis include parenchymal nodules in early stages. One study found that ground-glass opacities were more commonly seen on CT scan in berylliosis than in sarcoidosis. In later stages hilar lymphadenopathy, interstitial pulmonary fibrosis and pleural thickening. [20]

Classification

Berylliosis is an occupational disease. [1] Relevant occupations are those where beryllium is mined, processed or converted into metal alloys, or where machining of metals containing beryllium and recycling of scrap alloys occurs. [21] It is associated with aerospace manufacturing, microwave semiconductor electronics, beryllium mining or manufacturing of fluorescent light bulbs (which once contained beryllium compounds in their internal phosphor coating). [22] [23] [24] Beryllia was used in lamp manufacture because of ceramic's obvious virtues for insulation and heat resistance, and also because beryllia could be made transparent. [25] Certain welding anodes along with other electrical contacts and even non-sparking tools are made of beryllium copper alloy and the subsequent machining of such materials would cause the disease as well.

Prevention

Typical levels of beryllium that industries may release into the air are of the order of 0.01 µg/m3, averaged over a 30-day period, or 2 µg/m3 of workroom air for an 8-hour work shift. Compliance with the current U.S. Occupational Safety and Health Administration (OSHA) permissible exposure limit for beryllium of 2 µg/m3 has been determined to be inadequate to protect workers from developing beryllium sensitization and chronic beryllium disease. The American Conference of Governmental Industrial Hygienists (ACGIH), which is an independent organization of experts in the field of occupational health, has proposed a threshold limit value (TLV) of 0.05 µg/m3 in a 2006 Notice of Intended Change (NIC). This TLV is 40 times lower than the current OSHA permissible exposure limit, reflecting the ACGIH analysis of best available peer-reviewed research data concerning how little airborne beryllium is required to cause sensitization and chronic beryllium disease.[ citation needed ]

Because it can be difficult to control industrial exposures to beryllium, it is advisable to use any methods possible to reduce airborne and surface contamination by beryllium, to minimize the use of beryllium and beryllium-containing alloys whenever possible, and to educate people about the potential hazards if they are likely to encounter beryllium dust or fumes. [26] It is important to damp wipe metallographic preparation equipment to prevent accumulation of dry particles. Sectioning, grinding, and polishing must be performed under sufficiently vented hoods equipped with special filters. [27]

On 29 January 2009, the Los Alamos National Laboratory announced it was notifying nearly 2,000 current and former employees and visitors that they may have been exposed to beryllium in the lab and may be at risk of disease. Concern over possible exposure to the material was first raised in November 2008, when a box containing beryllium was received at the laboratory's short-term storage facility. [28]

Treatment

There is no cure for berylliosis; the goals of treatment are to reduce symptoms and slow the progression of disease. [10] [29]

Although the evidence that stopping exposure to beryllium decreases progression of the disease is limited, [30] it is still considered to be an accepted approach to treatment in any stage of disease. [31]

People with early stages of disease, without lung function abnormalities or clinical symptoms, are periodically monitored with physical exams, pulmonary function testing and radiography. [29]

Once clinical symptoms or significant abnormalities in pulmonary function testing appear, treatments include oxygen and oral corticosteroids and whatever supportive therapy is required. [1] [15] [29]

Outcomes

Overall mortality rates are 5–38%. [32]

Epidemiology

The number of workers in the United States exposed to beryllium vary but has been estimated to be as high as 800,000 during the 1960s and 1970s. [33] A more recent study from 2004 estimated the number of exposed workers in the United States to be around 134,000. [34]

The rate of workers becoming sensitized to beryllium varies based on genetics and exposure levels. In one study researchers found the prevalence of beryllium sensitization to range from 9–19% depending on the industry. [35] Many workers who are found to be sensitive to beryllium also meet the diagnostic criteria for chronic beryllium disease. [35] In one study of nuclear workers, among those who were sensitized to beryllium, 66% were found to have chronic beryllium disease as well. [36] The rate of progression from beryllium sensitization to chronic beryllium disease has been estimated to be approximately 6–8% per year. [30] [37] Stopping exposure to beryllium in those sensitized has not been definitively shown to stop the progression to chronic beryllium disease. [30]

The overall prevalence of chronic beryllium disease among workers exposed to beryllium has ranged from 1–5% depending on industry and time period of study. [35] [36] [38]

The general population is unlikely to develop acute or chronic beryllium disease because ambient air levels of beryllium are normally very low (<0.03 ng/m3). [39] However, a study found 1% of people living within 3/4 of a mile of a beryllium plant in Lorain, Ohio, had berylliosis after exposure to concentrations estimated to be less than 1 milligram per cubic metre of air. In the United States the Beryllium Case Registry contained 900 records, early cases relating to extraction and fluorescent lamp manufacture, later ones coming from the aerospace, ceramics and metallurgical industries. [40] [41]

History

Since the 1920s, beryllium has been used in electronics, ceramics, research and development labs, aircraft, and the atomic energy and defense industry. [26] Cases of bronchitis and pneumonia-like symptoms were reported in Germany and Russia in the 1930s among workers mining and refining beryllium. By 1946, a cluster of cases associated with fluorescent lamp manufacturers were apparent in the United States, and the lamp industry stopped using beryllium in 1949. [31] At that time, most construction trades and industries were unaware of the potential risks associated with beryllium exposure. [42]

It occasionally killed early workers in nuclear weapons design, such as Herbert L. Anderson. [43]

Beryllium sensitivity testing was first performed as a cutaneous beryllium patch test in the early 1950s, but was discontinued due to the test stimulating sensitization or aggravating existing chronic beryllium disease. [44] : 115 

In the 1990s, the DOE began screening employees using the BeLPT test in facilities where beryllium was used, to take preventive measures against beryllium exposure. Somewhat alarmingly, clerical staff who were never involved in handling the material had developed asymptomatic sensitivities. [45]

Related Research Articles

<span class="mw-page-title-main">Sarcoidosis</span> Medical condition

Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. The disease usually begins in the lungs, skin, or lymph nodes. Less commonly affected are the eyes, liver, heart, and brain, though any organ can be affected. The signs and symptoms depend on the organ involved. Often, no, or only mild, symptoms are seen. When it affects the lungs, wheezing, coughing, shortness of breath, or chest pain may occur. Some may have Löfgren syndrome with fever, large lymph nodes, arthritis, and a rash known as erythema nodosum.

<span class="mw-page-title-main">Pneumoconiosis</span> Class of interstitial lung diseases

Pneumoconiosis is the general term for a class of interstitial lung disease where inhalation of dust has caused interstitial fibrosis. The three most common types are asbestosis, silicosis, and coal miner's lung. Pneumoconiosis often causes restrictive impairment, although diagnosable pneumoconiosis can occur without measurable impairment of lung function. Depending on extent and severity, it may cause death within months or years, or it may never produce symptoms. It is usually an occupational lung disease, typically from years of dust exposure during work in mining; textile milling; shipbuilding, ship repairing, and/or shipbreaking; sandblasting; industrial tasks; rock drilling ; or agriculture. It is one of the most common occupational diseases in the world.

<span class="mw-page-title-main">Asbestosis</span> Pneumoconiosis caused by inhalation and retention of asbestos fibers

Asbestosis is long-term inflammation and scarring of the lungs due to asbestos fibers. Symptoms may include shortness of breath, cough, wheezing, and chest tightness. Complications may include lung cancer, mesothelioma, and pulmonary heart disease.

<span class="mw-page-title-main">Granuloma</span> Aggregation of macrophages in response to chronic inflammation

A granuloma is an aggregation of macrophages that forms in response to chronic inflammation. This occurs when the immune system attempts to isolate foreign substances that it is otherwise unable to eliminate. Such substances include infectious organisms including bacteria and fungi, as well as other materials such as foreign objects, keratin, and suture fragments.

<span class="mw-page-title-main">Silicosis</span> Pneumoconiosis caused by inhalation of silica, quartz or slate particles

Silicosis is a form of occupational lung disease caused by inhalation of crystalline silica dust. It is marked by inflammation and scarring in the form of nodular lesions in the upper lobes of the lungs. It is a type of pneumoconiosis. Silicosis, particularly the acute form, is characterized by shortness of breath, cough, fever, and cyanosis. It may often be misdiagnosed as pulmonary edema, pneumonia, or tuberculosis. Using workplace controls, silicosis is almost always a preventable disease.

<span class="mw-page-title-main">Interstitial lung disease</span> Group of diseases

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Neurosarcoidosis</span> Medical condition

Neurosarcoidosis refers to a type of sarcoidosis, a condition of unknown cause featuring granulomas in various tissues, in this type involving the central nervous system. Neurosarcoidosis can have many manifestations, but abnormalities of the cranial nerves are the most common. It may develop acutely, subacutely, and chronically. Approximately 5–10 percent of people with sarcoidosis of other organs develop central nervous system involvement. Only 1 percent of people with sarcoidosis will have neurosarcoidosis alone without involvement of any other organs. Diagnosis can be difficult, with no test apart from biopsy achieving a high accuracy rate. Treatment is with immunosuppression. The first case of sarcoidosis involving the nervous system was reported in 1905.

<span class="mw-page-title-main">Hypersensitivity pneumonitis</span> Medical condition

Hypersensitivity pneumonitis (HP) or extrinsic allergic alveolitis (EAA) is a syndrome caused by the repetitive inhalation of antigens from the environment in susceptible or sensitized people. Common antigens include molds, bacteria, bird droppings, bird feathers, agricultural dusts, bioaerosols and chemicals from paints or plastics. People affected by this type of lung inflammation (pneumonitis) are commonly exposed to the antigens by their occupations, hobbies, the environment and animals. The inhaled antigens produce a hypersensitivity immune reaction causing inflammation of the airspaces (alveoli) and small airways (bronchioles) within the lung. Hypersensitivity pneumonitis may eventually lead to interstitial lung disease.

<span class="mw-page-title-main">Byssinosis</span> Medical condition

Byssinosis is an occupational lung disease caused by inhalation of cotton or jute dust in inadequately ventilated working environments and can develop over time with repeated exposure. Byssinosis commonly occurs in textile workers who are employed in yarn and fabric manufacture industries. It is now thought that the cotton dust directly causes the disease and some believe that the causative agents are endotoxins that come from the cell walls of gram-negative bacteria that grow on the cotton. Although bacterial endotoxin is a likely cause, the absence of similar symptoms in workers in other industries exposed to endotoxins makes this uncertain. Current smokers are also at risk for developing byssinosis or having complications relating to byssinosis.

Eosinophilic pneumonia is a disease in which an eosinophil, a type of white blood cell, accumulates in the lungs. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. Several different kinds of eosinophilic pneumonia exist and can occur in any age group. The most common symptoms include cough, fever, difficulty breathing, and sweating at night. Eosinophilic pneumonia is diagnosed by a combination of characteristic symptoms, findings on a physical examination by a health provider, and the results of blood tests and X-rays. Prognosis is excellent once most eosinophilic pneumonia is recognized and treatment with corticosteroids is begun.

<span class="mw-page-title-main">Bronchiolitis obliterans</span> Medical condition

Bronchiolitis obliterans (BO), also known as obliterative bronchiolitis, constrictive bronchiolitis and popcorn lung, is a disease that results in obstruction of the smallest airways of the lungs (bronchioles) due to inflammation. Symptoms include a dry cough, shortness of breath, wheezing and feeling tired. These symptoms generally get worse over weeks to months. It is not related to cryptogenic organizing pneumonia, previously known as bronchiolitis obliterans organizing pneumonia.

Occupational lung diseases comprise a broad group of diseases, including occupational asthma, industrial bronchitis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, inhalation injury, interstitial lung diseases, infections, lung cancer and mesothelioma. These can be caused directly or due to immunological response to an exposure to a variety of dusts, chemicals, proteins or organisms. Occupational cases of interstitial lung disease may be misdiagnosed as COPD, idiopathic pulmonary fibrosis, or a myriad of other diseases; leading to a delay in identification of the causative agent.

<span class="mw-page-title-main">Idiopathic pulmonary fibrosis</span> Medical condition

Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing alveolitis, is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue. It is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. The tissue in the lungs becomes thick and stiff, which affects the tissue that surrounds the air sacs in the lungs. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired, and abnormally large and dome shaped finger and toenails. Complications may include pulmonary hypertension, heart failure, pneumonia or pulmonary embolism.

<span class="mw-page-title-main">Bird fancier's lung</span> Type of hypersensitivity pneumonitis

Bird fancier's lung (BFL), also known as bird breeder's lung, is a type of hypersensitivity pneumonitis. It can cause shortness of breath, fever, dry cough, chest pain, anorexia and weight loss, fatigue, and progressive pulmonary fibrosis. It is triggered by exposure to avian proteins present in the dry dust of droppings or feathers of a variety of birds. The lungs become inflamed, with granuloma formation. It mostly affects people who work with birds or own many birds.

The Kveim test, Nickerson-Kveim or Kveim-Siltzbach test is a skin test used to detect sarcoidosis, where part of a spleen from a patient with known sarcoidosis is injected into the skin of a patient suspected to have the disease. If non caseating granulomas are found, the test is positive. If the patient has been on treatment, the test may return a false negative result. The test is not commonly performed, and in the UK no substrate has been available since 1996. There is a concern that certain infections, such as bovine spongiform encephalopathy, could be transferred through a Kveim test.

Occupational asthma is new onset asthma or the recurrence of previously quiescent asthma directly caused by exposure to an agent at workplace. It is an occupational lung disease and a type of work-related asthma. Agents that can induce occupational asthma can be grouped into sensitizers and irritants.

<span class="mw-page-title-main">Beryllium granuloma</span> Medical condition

Beryllium granulomas is a skin condition caused by granulomatous inflammation of the skin which may follow accident laceration, usually in the occupational setting.

Acute beryllium poisoning is acute chemical pneumonitis resulting from the toxic effect of beryllium in its elemental form or in various chemical compounds, and is distinct from berylliosis. After occupational safety procedures were put into place following the realization that the metal caused berylliosis around 1950, acute beryllium poisoning became extremely rare.

<span class="mw-page-title-main">Flock worker's lung</span> Occupational disease

Flock worker's lung is an occupational lung disease caused by exposure to flock, small fibers that are glued to a backing in order to create a specific texture. People who work in flocking are at risk of inhaling small pieces of the flock fibers, which causes interstitial lung disease. The disease was initially described in 1998, when a group of workers at a flocking plant developed interstitial lung disease of unknown cause.

Indium lung is a rare occupational lung disease caused by exposure to respirable indium in the form of indium tin oxide. It is classified as an interstitial lung disease.

References

  1. 1 2 3 4 OSHA Beryllium Health Effects Page accessed March 29, 2016
  2. ↑ Dweik, Raed A (2008-11-19). "Berylliosis: Treatment & Medication". Medscape. Retrieved 2009-08-21.
  3. ↑ Kriebel, D; Brain, JD; Sprince, NL; Kazemi, H (1988). "The pulmonary toxicity of beryllium". The American Review of Respiratory Disease. 137 (2): 464–73. doi:10.1164/ajrccm/137.2.464. PMID   3277503.
  4. ↑ Day, GA; Stefaniak, AB; Weston, A; Tinkle, SS (February 2006). "Beryllium exposure: dermal and immunological considerations". International Archives of Occupational and Environmental Health. 79 (2): 161–4. doi:10.1007/s00420-005-0024-0. PMID   16231190. S2CID   41564437.
  5. ↑ Kreider, ME; Rossman, MD (2015). "Chapter 87: Chronic beryllium disease and hard-metal lung diseases". In Grippi, MA; Elias, JA; Fishman, JA; Kotloff, RM; Pack, AI; Senior, RM (eds.). Fishman's Pulmonary Diseases and Disorders (5th ed.). McGraw-Hill. ISBN   978-0-07-179672-9.
  6. ↑ Falta, Michael T.; Pinilla, Clemencia; Mack, Douglas G.; Tinega, Alex N.; Crawford, Frances; Giulianotti, Marc; Santos, Radleigh; Clayton, Gina M.; Wang, Yuxiao (2013-07-01). "Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease". The Journal of Experimental Medicine. 210 (7): 1403–1418. doi:10.1084/jem.20122426. ISSN   0022-1007. PMC   3698527 . PMID   23797096.
  7. ↑ Freiman, D. G.; Hardy, H. L. (1970-03-01). "Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. beryllium case registry". Human Pathology. 1 (1): 25–44. doi:10.1016/S0046-8177(70)80003-X. ISSN   0046-8177. PMID   5521721.
  8. ↑ Sawyer, Richard T.; Maier, Lisa A.; Kittle, Lori A.; Newman, Lee S. (February 2002). "Chronic beryllium disease: a model interaction between innate and acquired immunity". International Immunopharmacology. 2 (2–3): 249–261. doi:10.1016/S1567-5769(01)00177-1. ISSN   1567-5769. PMID   11811929.
  9. ↑ Saltini, C.; Amicosante, M.; Franchi, A.; Lombardi, G.; Richeldi, L. (1998-12-01). "Immunogenetic basis of environmental lung disease: lessons from the berylliosis model". European Respiratory Journal. 12 (6): 1463–1475. doi: 10.1183/09031936.98.12061463 . ISSN   0903-1936. PMID   9877510.
  10. 1 2 Agency for Toxic Substances and Disease Registry via the CDC. Beryllium Toxicity: How Should Patients Exposed to Beryllium Be Treated and Managed? Page last updated: May 23, 2008
  11. 1 2 Rosenman KD, Rossman M, Hertzberg V, Reilly MJ, Rice C, Kanterakis E, Monos D (2011). "HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity". Occup Environ Med. 68 (7): 487–93. doi:10.1136/oem.2010.055046. PMID   21186201. S2CID   27610317.
  12. ↑ Clayton GM, Wang Y, Crawford F, Novikov A, Wimberly BT, Kieft JS, Falta MT, Bowerman NA, Marrack P, Fontenot AP, Dai S, Kappler JW (2014). "Structural Basis of Chronic Beryllium Disease: Linking Allergic Hypersensitivity and Autoimmunity". Cell. 158 (1): 132–142. doi:10.1016/j.cell.2014.04. Individuals carrying the MHCII allele, HLA-DP2, are at risk for chronic beryllium disease (CBD), a debilitating inflammatory lung condition caused by the reaction of CD4 T cells to inhaled beryllium.
  13. ↑ "IARC Monograph, Volume 58". International Agency for Research on Cancer. 1993. Retrieved 2008-09-18.
  14. ↑ Newman, LS (March 1995). "Beryllium disease and sarcoidosis: clinical and laboratory links". Sarcoidosis. 12 (1): 7–19. PMID   7617981.
  15. 1 2 3 4 Balmes, John R.; Abraham, Jerrold L.; Dweik, Raed A.; Fireman, Elizabeth; Fontenot, Andrew P.; Maier, Lisa A.; Muller-Quernheim, Joachim; Ostiguy, Gaston; Pepper, Lewis D. (2014). "An Official American Thoracic Society Statement: Diagnosis and Management of Beryllium Sensitivity and Chronic Beryllium Disease". American Journal of Respiratory and Critical Care Medicine. 190 (10): e34–e59. doi:10.1164/rccm.201409-1722st. PMID   25398119.
  16. ↑ Rossman, MD; Kreider, ME (June 2003). "Is chronic beryllium disease sarcoidosis of known etiology?". Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 20 (2): 104–9. PMID   12870719.
  17. ↑ Cheva, Angeliki; Kilmpasani, Maria; Stathakis, Eustathios; Dimitriadis, Ioannis; Mpikos, Vasileios; Papaemmanouil, Styliani (November 2016). "AB042. Sarcoidosis or Berylliosis? Two diseases with similar histologic findings". Annals of Translational Medicine. 4 (22): AB042. doi: 10.21037/atm.2016.AB042 . ISSN   2305-5839. PMC   5159372 .
  18. ↑ Frome, Edward L; Newman, Lee S; Cragle, Donna L; Colyer, Shirley P; Wambach, Paul F (2003-02-01). "Identification of an abnormal beryllium lymphocyte proliferation test". Toxicology. 183 (1–3): 39–56. doi:10.1016/S0300-483X(02)00439-0. PMID   12504341.
  19. ↑ Aronchick, J. M.; Rossman, M. D.; Miller, W. T. (1987-06-01). "Chronic beryllium disease: diagnosis, radiographic findings, and correlation with pulmonary function tests". Radiology. 163 (3): 677–682. doi:10.1148/radiology.163.3.3575713. ISSN   0033-8419. PMID   3575713.
  20. 1 2 Sharma, Nidhi; Patel, Jeet; Mohammed, Tan-Lucien H. (2010). "Chronic Beryllium Disease". Journal of Computer Assisted Tomography. 34 (6): 945–948. doi:10.1097/rct.0b013e3181ef214e. PMID   21084914.
  21. ↑ ATSDR. ToxGuide for Beryllium September 2002
  22. ↑ General Electric Fluorescent Lamps TP 111R, Dec. 1978, says on pg. 23 that since 1949 GE lamps used relatively inert phosphates found to be safe in ordinary handling of either the intact or broken lamp.
  23. ↑ Cooper, Ross G.; Harrison, Adrian P. (August 2009). "The uses and adverse effects of beryllium on health". Indian Journal of Occupational and Environmental Medicine. 13 (2): 65–76. doi: 10.4103/0019-5278.55122 . PMC   2847329 . PMID   20386622.
  24. ↑ Hardy, HL; Tabershaw, IR (1946). "Delayed chemical pneumonitis in workers exposed to beryllium compounds". Journal of Industrial Hygiene and Toxicology. 28: 197–211. PMID   21000285.
  25. ↑ Cayless, M A; Marsden, A M, eds. (1983). "7.2.1 Optical ceramics". Lamps and Lighting (3rd ed.). Edward Arnold. p. 127. ISBN   978-0-7131-3487-2.
  26. 1 2 Lang, Leslie (June–July 1994). "Beryllium: A Chronic Problem". Environmental Health Perspectives. 102 (6–7): 526–31. doi:10.1289/ehp.94102526. PMC   1569745 . PMID   9679108.
  27. ↑ Batich, Ray and James M. Marder. (1985) Beryllium In (Ed. 9), Metals Handbook: Metallography and Microstructures (pp. 389–391). Metals Park, Ohio: American Society for Metals.
  28. ↑ "Nearly 2,000 people warned of possible beryllium exposure". CNN. 29 January 2009.
  29. 1 2 3 Sood, Akshay (2009). "Current Treatment of Chronic Beryllium Disease". Journal of Occupational and Environmental Hygiene. 6 (12): 762–765. doi:10.1080/15459620903158698. PMC   2774897 . PMID   19894178.
  30. 1 2 3 Seidler, A.; Euler, U.; Müller-Quernheim, J.; Gaede, K. I.; Latza, U.; Groneberg, D.; Letzel, S. (2012-10-01). "Systematic review: progression of beryllium sensitization to chronic beryllium disease". Occupational Medicine. 62 (7): 506–513. doi: 10.1093/occmed/kqs069 . ISSN   0962-7480. PMID   22705916.
  31. 1 2 Rossman, M (1996). "Chronic beryllium disease: diagnosis and management". Environmental Health Perspectives. 104 (Suppl 5): 945–947. doi:10.1289/ehp.96104s5945. PMC   1469698 . PMID   8933039.
  32. ↑ Newman, LS; Lloyd, J; Daniloff, E (1996). "The natural history of beryllium sensitization and chronic beryllium disease". Environmental Health Perspectives. 104 (Suppl 5): 937–43. doi:10.2307/3433014. JSTOR   3433014. PMC   1469683 . PMID   8933038.
  33. ↑ Cullen, Mark; Cherniack, Martin; Kominsky, John (1986-01-01). "Chronic Beryllium Disease in the United States". Seminars in Respiratory and Critical Care Medicine. 7 (3): 203–209. doi:10.1055/s-2007-1012616. S2CID   72430473.
  34. ↑ Henneberger, Paul K.; Goe, Sandra K.; Miller, William E.; Doney, Brent; Groce, Dennis W. (2004-10-01). "Industries in the United States with Airborne Beryllium Exposure and Estimates of the Number of Current Workers Potentially Exposed". Journal of Occupational and Environmental Hygiene. 1 (10): 648–659. doi:10.1080/15459620490502233. ISSN   1545-9624. PMID   15631056. S2CID   19773286.
  35. 1 2 3 Kreiss, K.; Mroz, M. M.; Zhen, B.; Wiedemann, H.; Barna, B. (1997-08-01). "Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant". Occupational and Environmental Medicine. 54 (8): 605–612. doi:10.1136/oem.54.8.605. ISSN   1470-7926. PMC   1128986 . PMID   9326165.
  36. 1 2 Kreiss, K.; Mroz, M. M.; Zhen, B.; Martyny, J. W.; Newman, L. S. (1993-10-01). "Epidemiology of beryllium sensitization and disease in nuclear workers". The American Review of Respiratory Disease. 148 (4 Pt 1): 985–991. doi:10.1164/ajrccm/148.4_Pt_1.985. ISSN   0003-0805. PMID   8214955.
  37. ↑ Newman, Lee S.; Mroz, Margaret M.; Balkissoon, Ronald; Maier, Lisa A. (2005-01-01). "Beryllium Sensitization Progresses to Chronic Beryllium Disease". American Journal of Respiratory and Critical Care Medicine. 171 (1): 54–60. doi:10.1164/rccm.200402-190OC. ISSN   1073-449X. PMID   15374840.
  38. ↑ Henneberger, P. K.; Cumro, D.; Deubner, D. D.; Kent, M. S.; McCawley, M.; Kreiss, K. (2001-04-01). "Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant". International Archives of Occupational and Environmental Health. 74 (3): 167–176. doi:10.1007/s004200100237. ISSN   0340-0131. PMID   11355290. S2CID   39949745.
  39. ↑ National Research Council (U.S.). Committee on Beryllium Alloy Exposures, National Research Council (U.S.). Committee on Toxicology (2007). Health effects of beryllium exposure. National Academies Press. p. 11. ISBN   978-0-309-11167-6.
  40. ↑ David Geraint James, Alimuddin Zumla, The granulomatous disorders, Cambridge University Press, 1999, ISBN   0-521-59221-6, pages 336–337
  41. ↑ Brown University Medical School. "Berylliosis". Archived from the original on 2017-10-04. Retrieved 2012-08-20.
  42. ↑ Welch, L (2013). "Beryllium Disease Among Construction Trade Workers at Department of Energy Nuclear Sites". American Journal of Industrial Medicine. 56 (10): 1125–1136. doi:10.1002/ajim.22202. PMID   23794247.
  43. ↑ "Photograph of Chicago Pile One Scientists 1946". Office of Public Affairs, Argonne National Laboratory. 19 June 2006. Retrieved 2008-09-18.
  44. ↑ Agency for Toxic Substances and Disease Registry. September 2002 Toxicological Profile: Beryllium. See also 2009 Addendum
  45. ↑ Marshall, E (1999). "Science News: Beryllium screening raises ethical issues". Science. 285 (5425): 178–179. doi:10.1126/science.285.5425.178b. PMID   10428708. S2CID   11215967.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.